AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 171 min read$GLUE

Warmuth Markus sold $220K of GLUE

Warmuth Markus (President & CEO) sold 9,500 shares of Monte Rosa Therapeutics, Inc. (GLUE) at $23.18 ($0.22M total) on 2026-07-16.

Original reporting
SEC EDGAR · Warmuth Markus
Published Jul 17, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GLUE
Neutral
medium confidence
Mentioned
$GLUE
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLUENeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale details (shares, price, total value) and that it was not under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not change the company’s fundamentals.

03

What to watch

The article does not state whether the CEO has other holdings, prior sale patterns, or tax-related reasons; absence of a 10b5-1 plan does not prove intent.

Relevance 4/10Novelty 3/10Timing: after-hours filing timestamp on 2026-07-17 for a sale dated 2026-07-16

Background

The article is an SEC Form 4 insider transaction disclosure for Monte Rosa Therapeutics, Inc. (GLUE).

Company-level read

Ticker impact

$GLUENeutralMedium confidence
Context

SEC Form 4 shows GLUE CEO Warmuth sold 9,500 shares on 2026-07-16 for about $220.2K at $23.1809.

Expected impact

Likely limited near-term price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing discloses transaction size, price, and absence of a pre-arranged 10b5-1 plan, but provides no new company-specific operating or financial information.

Market effects

Sector

No clear sector read-through from a single CEO sale filing.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be for diversification or liquidity needs and does not necessarily signal reduced confidence in the business.

Key entities

  • issuer
    GLUE

    Monte Rosa Therapeutics, Inc., the company whose CEO filed the Form 4 insider sale.

  • insider
    Warmuth Markus

    President and CEO who sold 9,500 shares on 2026-07-16.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GLUE insider trading history →

Related articles

OCT 11
$GLUEMed

Monte Rosa Therapeutics assumed with a Buy at UBS

UBS initiated coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and $19 price target, citing the potential of its drug MRT-8102 for chronic inflammatory diseases. The firm highlights the drug's differentiated profile and the company's atherosclerotic cardiovascular disease opportunity.

tipranks.com1 min
OCT 5
$GLUEMedAI 8/10

H.C. Wainwright reiterates Monte Rosa stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $25.00 price target on Monte Rosa Therapeutics (GLUE) after positive clinical trial results for MRT-8102. The stock is currently trading at $10.50, down 10% over the past week. Jefferies also raised its price target to $40, maintaining a Buy rating. The company is conducting a phase 2 study for metastatic prostate cancer and expects further clinical data catalysts in 2026 and 2027.

investing.com2 min
OCT 3
$GLUEMedAI 8/10

Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win

Monte Rosa Therapeutics reported positive Phase 1 results for MRT-8102, showing significant biomarker reductions and no serious adverse events. The data supports its planned Phase 2b study in coronary artery disease. The company forecasts revenue of $88.1M and earnings of $15.2M by 2029, with current losses of $161.1M and revenue of $28.7M.

simplywall.st2 min
OCT 1
$GLUEMedAI 8/10

Monte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1

Monte Rosa Therapeutics (GLUE) reported Phase 1 results showing MRT-8102 achieved 80%-90% NEK7 degradation, reducing biomarkers linked to cardiovascular disease. The treatment was well-tolerated with no serious adverse events. GLUE plans Phase 2 trials in 2026-2027 for coronary artery disease, gout, and hidradenitis suppurativa. GLUE stock is currently down 5.74% at $11.24.

rttnews.com2 min